Akebia Therapeutics

Expanding Dialysis Access Will Unlock New CKD Treatment Frontiers

AnalystConsensusTarget

Not Invested

Consensus Narrative from 5 Analysts

Published

28 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$7.50

57.5% undervalued

15 Aug

US$3.19

108.5%

-1.8%

Author's Valuation

US$7.5

57.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 1.35%

AnalystConsensusTarget Fair Value

US$7.5

57.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.04%

Biotech revenue growth rate

11.97%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.02%

Calculation

US$91.31m

Earnings '28

53.46x

PE Ratio '28

US$4.88b

Market Cap '28

US$4.88b

Market Cap '28

531.48m

No. shares '28

US$9.19

Share Price '28

US$9.19 Share Price '28

Discounted to 2025 @ 6.99% p.a.

US$7.50

Fair Value '25

Expanding Dialysis Access Will Unlock New CKD Treatment Frontiers

Shared on01 May 25Fair value Increased 1.35%

Shared on01 May 25
Fair value Increased 1.35%